Table 1

Patient demographics and baseline characteristics

Patients (N=36)
Median age (range), years62.5 (43.0–79.0)
Sex
 Male28 (77.8%)
 Female8 (22.2%)
ECOG performance status
 011 (30.6%)
 125 (69.4%)
No. of organs of metastases
 114 (38.9%)
 26 (16.7%)
 >214 (38.9%)
Common visceral diseases
 Lung metastases17 (47.2%)
 Bone metastases8 (22.2%)
 Liver metastases8 (22.2%)
Subsite of primary tumor
 Bladder18 (50.0%)
 Renal pelvis10 (27.8%)
 Ureter5 (13.9%)
 Mixed2 (5.6%)
 Urethra1 (2.8%)
Prior surgery for primary tumor29 (80.6%)
Prior platinum-based therapies36 (100%)
 Adjuvant therapy1 (2.8%)
 One line31 (86.1%)
 Two lines4 (11.1%)
Previous systemic therapy
 Platinum in neoadjuvant or adjuvant settings*2 (5.6%)
 Platinum in advanced or metastatic settings35 (97.2%)
  Cisplatin-based regimen only24 (66.7%)
  Carboplatin-based regimen only4 (11.1%)
  Both cisplatin-based and carboplatin-based regimens1 (2.8%)
  Other platinum-based regimen6 (16.7%)
PD-L1 CPS in 27 evaluable patients
 <119 (70.4%)
 ≥18 (29.6%)
  • Data are n (%) unless stated otherwise.

  • *One patient had received platinum-based regimen both in neoadjuvant or adjuvant setting and advanced or metastatic setting.

  • CPS, Combined Positive Score; ECOG, Eastern Cooperative Group.